Traws Pharma, Inc. Logo

Traws Pharma, Inc.

Develops oral small-molecule therapies for respiratory viral diseases and cancer.

TRAW | US

Overview

Corporate Details

ISIN(s):
US68232V8845 (+1 more)
LEI:
Country:
United States of America
Address:
12 PENNS TRAIL, 18940 NEWTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company that develops novel, oral small-molecule therapies for respiratory viral diseases and cancer. The company focuses on advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains. Its pipeline includes Ratutrelvir, a ritonavir-independent treatment targeting the main protease (Mpro) for COVID-19 and Long COVID, and Tivoxavir marboxil, a single-dose therapy targeting the cap-dependent endonuclease (CEN) for bird flu and seasonal influenza. Traws Pharma aims to develop safe product candidates with simple dosing regimens and utilizes accelerated clinical trial strategies for vulnerable patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Traws Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Traws Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Traws Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden
KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America
KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America
KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea
038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea
256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan
4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland
KNRS
Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America
KNSA
KIORA PHARMACEUTICALS INC Logo
Developing advanced small molecule therapies for vision-threatening retinal diseases.
United States of America
KPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.